Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin added to metformin for metabolic factors and liver enzymes in type 2 diabetes with nonalcoholic fatty liver
IRCT20191209045671N2Phase 3Completed
- Sponsor
- Semnan University of Medical Sciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Semnan University of Medical Sciences. Primary endpoints: Blood glucose, Triglycerides and 3 more. Started Feb 2022; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20191209045671N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191209045671N2.